- on various factors, including clearance of the molecu
- lar structures and the amount of cartilage matrix1. Myers SL. Synovial ? uid markers in osteoarthritis. Rheum Dis Clin North Am 1999;25:433-49.
- remaining in the joint. Besides, the majority of the 2. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne
- markers are not only produced in articular cartilage R, Rorabeck C, et al. Enhanced cleavage of type II collagen
- but to varying extents also in the synovial membrane by collagenases in osteoarthritic articular cartilage. J Clin
- and other organs. Invest 1997;99:153 4-45. 3. Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier
- Tenascin and MMP-13 might be a helpful tool in
- J. The new collagenase, collagenase-3, is expressed and synthe-Ja¨rvinen M. Tenascin-C in the pathophysiology and healing process of musculoskeletal tissue injury. Scand J Med Sci
- sized by human chondrocytes but not in synoviocytes: a role Sports 2000;10:376-2.
- in osteoarthritis. J Clin Invest 1996;97:2011-9. 22. Salter DM. Tenascin is increased in cartilage and synovium
- Johansen JS, Jensen HS, Price PA. A new biochemical marker from arthritic knees. Br J Rheumatol 1993;32:780-6.
- for joint injury. Analysis of YKL-40 in serum and synovial 23. Natali PG, Nicotra MR, Bigotti A, Bartolazze A, Motolese
- ? uid. Br J Rheumatol 1993;32:949-55. M, Coscia N, et al. Comparative analysis of the expression of
- Conrozier T, Carlier MC, Mathieu P, Colson F, Debard AL, the extra-cellular matrix protein tenascin in normal humanRichard S, et al. Serum levels of YKL-40 and C reactive fetal, adult and tumor tissues. Int J Cancer 1991;47:811-6.protein in patients with hip osteoarthritis and healthy subjects: 24. Ja¨rvinen TA, Jozsa L, Kannus P, Ja¨rvinen TLN, Kvist M,
- a cross sectional study. Ann Rheum Dis 2000;59:828-31. Hurme T, et al. Mechanical loading regulates tenascin-c expres-
- Jones FS, Jones PL. The tenascin family of ECM glycoproteins: sionintheosteotendineousjunction.JCellScistructure, function, and regulation during embryonic develop-1999;112:3157-66.ment and tissue remodeling. Dev Dyn 2000;218:23 5-59. 25. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix
- Chevalier X, Groult N, Larget-Piet B, Zardi L, Hornebeck W. metalloproteinases: structures, evolution, and diversi? cation.
- Tenascin distribution in articular cartilage from normal sub-FASEB J 1998;12:1075-95.
- jects and from patients with osteoarthritis and rheumatoid 26. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL,
- arthritis. Arthritis Rheum 1994;37:101 3-22. Yocum SA, Rosner PJ, et al. Cloning, expression, and type II
- Dahlberg L, Roos H, Saxne T, Heinegard D, Lark MW, collagenolytic activity of matrix metalloproteinase-13 fromHoerrner LA, et al. Cartilage metabolism in the injured and human osteoarthritic cartilage. J Clin Invest 1996;97:761-8.
- uninjured knee of the same patient. Ann Rheum Dis 27. Wernicke D, Seyfert C, Hinzmann B, Gromnica-Ihle E.
- 1994;53:823-7. Cloning of collagenase-3 from the synovial membrane and its
- Lohmander LS, Hoerrner LA, Dahlberg L, Roos H, Bjo¨rnsson expression in rheumatoid arthritis and osteoarthritis. J
- S, Lark MW. Stromelysin, tissue inhibitor of metallo-Rheumatol 1996;23:590-5.
- proteinases and proteoglycan fragments in human knee joint 28. Lohmander LS, Hoerrner LA, Dahlberg L, Roos H, Bjo¨ rnsson
- ? uid after injury. J Rheumatol 1993;20:1362-8. S, Lark MW. Stromelysin, tissue inhibitor of metallo-
- Outerbridge RE. The etiology of chondromalacia patellae. J proteinases and proteoglycan fragments in human knee joint
- Bone Joint Surg [Br] 1961;43-B:752-7. ? uid after injury. J Rheumatol 1993;20:136 2-8.
- Noyes FR, Stabler CL. A system for grading articular cartilage 29. Naito K, Takahashi M, Kushida K, Suzuki M, Ohishi T,
- lesions at arthroscopy. Am J Sports Med 1989;17:505-13. Miura M, et al. Measurement of matrix metalloproteinases
- Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1)
- K, et al. Development of criteria for the classi? cation and in patients with knee osteoarthritis: comparison with general-
- reporting of osteoarthritis of the knee. Arthritis Rheum ized osteoarthritis. Rheumatology 1999;38:510-5.
- 1986;29:1039-49. 30. Ishiguro N, Ito T, Ito H, Iwata H, Jugessur H, Ionescu M,
- Lequesne M, Mery C, Samson M, Gerard P. Indices of severity et al. Relationship of matrix metalloproteinases and their
- for osteoarthritis of the hip and the knee. Validation - value inhibitor to cartilage proteoglycan and collagen turnover.
- in comparison with other assessment tests. Scand J Rheumatol Arthritis Rheum 1999;42:129-36.
- 1987;16 Suppl 65:85-9. 31. Neidhart M, Hauser N, Paulsson M, DiCesare PE, Michel
- Bellamy N, Buchanan WW, Goldsmith CH, Campbell, Stitt BA, Hauselmann HJ. Small fragments of oligomeric matrix
- LW. Validation of WOMAC: a health status instrument for protein in synovial ? uid and serum as markers for cartilage
- measuring clinically important patient relevant outcomes to degradation. Br J Rheumatol 1997;36:1151-60.
- antirheumatic drug therapy in patients with osteoarthritis of 32. Lohmander LS, Saxne T, Heinegard D, Release of cartilage
- the hip or the knee. J Rheumatol 1988;15:183 3-40. oligomeric matrix protein (COMP) into joint ? uid after knee
- RoosEM,Kla¨ssboM,LohmanderLS.WOMAC injury and in osteoarthritis. Ann Rheum Dis 1992;53:8-13.
- osteoarthritis index. Reliability, validity, and responsiveness in 33. Sharif M, Saxne T, Shepstone L, Kirwan JR, Elson CJ, Dieppe
- patients with arthroscopically assessed osteoarthritis. Scand J PA. Relationship between serum cartilage oligomeric matrix
- Rheumatol 1999;28:210-5. protein levels and disease progression in osteoarthritis of the
- Kellgren JH, Lawrence JS. Radiological assessment of knee joint. Br J Rheumatol 1995;34:306-10.
- osteoarthritis. Ann Rheum Dis 1957;16:494-501. 34. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD,
- Ayral X, Altman R. Arthroscopic evaluation of knee articular Luta G, et al. Serum cartilage oligomeric matrix protein re? ects
- cartilage. In: Brandt KD, Doherty M, Lohmander LS (1998). osteoarthritispresenceandseverity.ArthritisRheum
- Osteoarthritis. Oxford University Press, Oxford, UK. 1999;42:2356-64.
- Lohmander LS, Dahlberg L, Ryd L, Heinegard D. Increased35. Volck B, Ostergaard K, Johansen JS, Garbarsch C, Price PA.
- levels of proteoglycan fragments in knee joint ? uid after injury.The distribution of YKL-40 in osteoarthritic and normal
- Arthritis Rheum 1989;32:1434-42.human articular cartilage. Scand J Rheumatol 1999;28:171-9.
- Va¨a¨ta¨inen U, Lohmander LS, Thonar EJ, Hongisto T, Agren36. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I,
- U, Ro¨ nkko¨ S, et al. Markers of cartilage and synovial metabol-Price PA. Serum YKL-40 levels in healthy children and adults.
- ism in joint ? uid and serum of patients with chondromalaciaComparison with serum and synovial ? uid levels of YKL-40
- of the patella. Osteoarthritis Cartilage 1998;6:115-24.in patients with osteoarthritis or trauma of the knee joint. Br
- Mackie EJ, ThesleV I, Chiquet-Erishmann R. Tenascin isJ Rheumatol 1996;35:553-9.
- associated with chondrogenic and osteogenic diVerentiation in37. Harvey S, Whaley J, Eberhardt K. The relationship between
- vivio and promotes chondrogenesis in vitro. J Cell Biolserum levels of YKL-40 and disease progression in patients
- 1987;105:2569-79.withearlyrheumatoidarthritis.ScandJRheumatol 2000;29:391-3.
- Ja¨rvinen TAH, Kannus P, Ja¨rvinen TLN, Jozsa L, Kalimo H,
Scandinavian Journal of Rheumatology
Volume 31, 2002 - Issue 3